Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hiroshima
Clinical trial register · Japan

Clinical Trials in Hiroshima, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca56 Hoffmann-La Roche13 GlaxoSmithKline11 Ono Pharmaceutical Co., Ltd.8 Eli Lilly and Company7
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Hiroshima

219 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
National Cancer Center, Japan
Phase 2
27
Fukuoka, Hiroshima, Nagoya, Takatsuki, Tokyo
2027-01-01
Not yet open
Study of BK1803 in Healthy Infants
NCT07793513Pertussis, Diphtheria, Tetanus, Poliomyelitis
Tanabe Pharma Corporation
Phase 3
344
Fukui-shi, Fukuoka, Isesaki, Maebashi, Hiroshima, Ishikari-shi, Sapporo, Amagasaki
2026-10
Recruiting
AstraZeneca
Phase 3
1,330
Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe
2026-09-15
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1/2
50
Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto
2026-09-15
Not yet open
Breakthrough Platform Trial for PCAS
NCT07769086Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
630
Chiba, Iizuka, Hiroshima, Kobe, Kita-gun, Kyoto, Sendai, Okayama
2026-09-01
Recruiting
National Cancer Center, Japan
Phase 2
136
Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina
2026-07-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Kakogawa-shi, Kumagaya-shi, Kumamoto, Matsusaka-shi
2026-06-11
Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia, Stroke (CVA) or TIA
DrugPemafibrate
Tokyo Women's Medical University
Not applicable
270
Toyoake, Yachiyo, Fukuyama, Hiroshima, Kobe, Tsukuba, Hizume, Kagoshima
2026-05-26
Recruiting
BeOne Medicines
Phase 3
1,056
Kurumeshi, Otashi, Hiroshima, Sapporo, Nishinomiyashi, Kagoshima, Iseharashi, Kawasakishi
2026-05-22
Recruiting
Ipsen
Phase 3
350
Chiba, Hiroshima, Itabashi-ku, Yokohama, Ōmura, Kashihara, Niigata, Suita
2026-05-14
Recruiting
Novo Nordisk A/S
Phase 3
300
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
2026-05-05
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Fukuoka, Hiroshima, Sapporo, Yokohama, Tokyo, Natori-shi, Niigata, Hirakata
2026-04-28
Recruiting
Takeda
Phase 2
42
Tokyo, Fukui, Hiroshima, Kanagawa, Fukuoka, Hyōgo, Yamanashi, Ehime
2026-04-22
Active, closed
AbbVie
Phase 2
14
Nagoya, Yoshida-gun, Fukuoka, Maebashi, Hiroshima, Higashiibaraki-gun, Kyoto, Sakai-shi
2026-03-17
Not yet open
Evidence-Based Nursing to Reduce Adverse Events Regarding Ventilator Associated Pneumonia, Pressure Injuries and Central Line Bloodstream Infection in Intensive Care Unit in Bangladesh
NCT07299799Ventilator Acquired Pneumonia, Central Line Associated Blood Stream Infections (CLABSI), Pressure Ulcer (PU), Medical Device Related Pressure Ulcer (MDRPU)
Hiroshima University
Not applicable
272
Hiroshima
2026-02-15
Recruiting
GlaxoSmithKline
Phase 1
44
Fukuoka, Hiroshima, Hokkaido
2026-02-10
Recruiting
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
NCT07605819Pancreatic Cancer, Pancreatic Neoplasms
Cosomil, Inc.
Not applicable
10,000
Nagakute, Nagoya, Hiroshima, Onomichi, Obihiro, Sapporo, Kobe, Mito
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi
2026-02-03
Recruiting
Tokyo Women's Medical University
Phase 3
950
Akita, Chiba, Fukuoka, Fukushima, Fukuyama, Hamamatsu, Hirakata, Hiroshima
2026-01-28
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Hiroshima, Nagoya, Shizuoka, Tokyo
2026-01-26
Recruiting
Generate Biomedicines
Phase 3
786
Seto-shi, Matsuyama, Fukui-shi, Iizuka-Shi, Isesaki-Shi, Hiroshima, Asahikawa-shi, Himeji
2026-01-20
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Nagoya, Kurume-Shi, Hiroshima, Sapporo, Fukuoka, Akashi, Kobe, Yokohama
2025-12-22
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Hiroshima, Asahikawa, Bunkyo-ku, Fuchu-shi, Setagaya-ku, Shinjuku-ku
2025-12-11
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
14
Nagoya, Fukuoka, Hiroshima, Sapporo, Kyoto, Sendai, Niigata, Ōsaka-sayama
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
600
Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido
2025-11-18
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Hiroshima, Hyōgo, Kagawa, Kochi, Okayama, Osaka, Tokyo
2025-11-12
Recruiting
AstraZeneca
Phase 3
400
Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama
2025-10-31
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
AbbVie
Observational
200
Nagakute, Nagoya, Hirosaki, Chiba, Kashiwa-shi, Sakura, Fukuoka, Hiroshima
2025-10-09
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Chiba, Fukui-shi, Gamagōri, Hamamatsu, Higashiibaraki-gun, Hiroshima, Kagawa, Kagoshima
2025-10-03
Recruiting
Sanofi
Phase 3
124
Kitakyushu, Hiroshima, Sapporo, Kobe, Kahoku, Uchinada, Kanazawa, Nagaoka, Hirakata
2025-09-26
Recruiting
Sanofi
Phase 4
35
Kawasaki, Hiroshima, Saitama, Tokyo
2025-09-23
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Bunkyō-Ku, Hiroshima, Kōriyama, Saga
2025-09-16
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Akita, Asahikawa, Fukuoka, Hidaka, Hiroshima, Kobe, Matsuyama, Nagoya
2025-09-08
Recruiting
BeOne Medicines
Phase 3
500
Nagoya, Nakamuraku, Matsuyama, Fukushima, Hiroshima, Sapporo, Nankoku, Kumamoto
2025-09-04
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Aomori, Bunkyō City, Chūōku, Hiroshima, Izunokuni, Osaka, Saga, Shimotsuke
2025-08-22
Recruiting
Bristol-Myers Squibb
Phase 3
586
Inage, Matsudo, Hiroshima, Kita-gun, Kamakura, Kawasaki, Ina, Kashiwazaki
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Kamogawa, Matsuyama, Hiroshima, Morioka, Kamakura, Tsu, Miyazaki, Hirakata
2025-07-18
Recruiting
Takeda
Phase 3
347
Kasugai-Shi, Nagoya, Toyoake-shi, Chiba, Fukuoka, Fukushima, Hiroshima, Sapporo
2025-07-15
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku
2025-07-02
Recruiting
AstraZeneca
Phase 2
987
Chiba, Fukuoka, Fukushima, Ginowan-shi, Hachioji-shi, Hamamatsu, Hiroshima, Izumi-shi
2025-06-27
Recruiting
Yukinori Ozaki
Phase 2
24
Nagoya, Kashiwa-shi, Gifu, Hiroshima, Sapporo, Akashi-shi, Okayama, Osaka
2025-06-24
Recruiting
AstraZeneca
Phase 3
1,220
Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe
2025-05-06
Recruiting
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
NCT06803823Agitation Associated With Alzheimer's Disease Dementia
DrugONO-2020
Ono Pharmaceutical Co., Ltd.
Phase 2
90
Aichi, Akita, Aomori, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido
2025-05-01
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Aichi, Chiba, Fukushima, Gunma, Hiroshima, Hyōgo, Ibaraki, Kagawa
2025-04-24
Recruiting
BeOne Medicines
Phase 3
250
Nagoya, Chiba, Matsuyama, Hiroshima, Sapporo, AmagasakiCity, Kagoshima, KyotoShi
2025-04-10
Recruiting
Hoffmann-La Roche
Phase 3
450
Aichi, Chiba, Fukushima, Hiroshima, Hokkaido, Kanagawa, Okayama, Saitama
2025-04-09
Recruiting
Gilead Sciences
Phase 3
695
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe
2025-04-04
Recruiting
Daiichi Sankyo
Phase 3
510
Chūōku, Hiroshima, Kashiwa, Kita-gun, Kobe, Kōtoku, Matsuyama, Nagoya
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Fukuoka, Ginowan-shi, Hiroshima, Ishinomaki, Kawaguchi-shi, Kiyose-shi, Kobe, Meguro-ku
2025-03-26
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Fukuoka, Tsu, Kawagoe, Saitama, Hiroshima, Kawasaki, Nagasaki, Saga
2025-03-20
Recruiting
BeOne Medicines
Phase 3
300
Nagoya, Toyohashishi, Chiba, Matsuyama, Ōgaki, Hiroshima, Sapporo, KobeShi
2025-03-05
Recruiting
AstraZeneca
Phase 3
840
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hidaka-shi, Hirakata-shi, Hiroshima, Kasama-shi
2025-03-01
Recruiting
Daiichi Sankyo
Phase 3
726
Bunkyō City, Chūōku, Gifu, Hiroshima, Kashiwa-shi, Kitakyushu, Kochi, Kōtoku
2025-02-27
Active, closed
GlaxoSmithKline
Phase 2
307
Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo
2025-02-10
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2025-02-01
Recruiting
Incyte Corporation
Phase 3
240
Aichi, Aichi-ken, Fukuoka, Hiroshima, Hyōgo, Isehara Kanagawa, Kumamoto Kumamoto, Maebashi
2025-01-21
Active, closed
Ipsen
Phase 3
18
Chiba, Fukushima, Hiroshima, Hokkaido, Kagawa, Kagoshima, Nagano, Nagasaki
2025-01-16
Active, closed
argenx
Phase 3
631
Nagoya, Fukushima, Hiroshima, Sapporo, Nishinomiya-shi, Tsukuba, Kahoku-gun, Kanazawa
2025-01-15
Recruiting
BioNTech SE
Phase 2/3
1,580
Ageo, Akashi, Aomori, Bunkyō City, Chūōku, Funabashi, Himeji, Hiroshima
2025-01-07
Recruiting
Rakuten Medical, Inc.
Phase 3
412
Aichi, Hiroshima, Kyoto, Tokyo, Yonago
2024-12-24
Recruiting
GlaxoSmithKline
Phase 3
514
Aichi, Gunma, Hiroshima, Hokkaido, Tokushima, Tokyo, Yamanashi
2024-12-12
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hiroshima, Kawagoe-shi, Kawasaki-shi, Kitaadachi-gun
2024-11-27
Active, closed
Genmab
Phase 3
191
Matsuyama, Kitakyushu-shi, Hiroshima, Kobe, Kumamoto, Osakasayama-shi, Bunkyō City, Chūōku
2024-11-25
By invitation
CoreTissue BioEngineering Inc.
Not applicable
64
Hirosaki, Hiroshima, Sapporo, Kobe, Bunkyo-ku, Shinjuku-ku
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Akashi-shi, Takamatsu, Chuo Ku, Chuo-ku Osaka-shi, Gifu, Hamamatsu, Hiroshima, Izumi-shi
2024-11-22
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hirakata-shi, Hiroshima, Kakogawa-shi, Kanazawa
2024-11-18
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 1/2
10
Hiroshima, Okinawa, Tokyo, Tsu
2024-11-05
By invitation
Hiroshima University
Observational
1,000
Hiroshima
2024-11-01
Active, closed
AstraZeneca
Phase 3
25
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa
2024-10-15
Active, closed
Eli Lilly and Company
Phase 2
143
Chiba, Chikushino-shi, Fukuoak, Hachinohe-shi, Hirosaki, Hiroshima, Isehara, Isesaki-shi
2024-10-10
Recruiting
Hiroshima University
Not applicable
272
Hiroshima
2024-10-10
Active, closed
Ipsen
Phase 2
670
Fukuoka, Hiroshima, Hyōgo, Kagoshima, Kyoto, Miyagi, Osaka, Shizuoka
2024-10-10
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nagoya, Toyoake, Yokohama, Iruma-gun, Bunkyo-ku, Shinjuku Ku, Toyama, Hiroshima
2024-10-09
Active, closed
AstraZeneca
Phase 3
768
Bunkyō City, Fukuoka, Hiroshima, Iruma-Gun, Iwakuni-shi, Kobe, Kōtoku, Kumamoto
2024-10-04
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Nagakute, Nagoya, Narita, Matsuyama, Fukuoka, Hiroshima, Kobe, Hitachi
2024-10-01
Active, closed
ModernaTX, Inc.
Phase 3
37,864
Nagoya, Hiroshima, Sapporo, Fukuoka, Kawasaki-shi, Kyoto, Minoh, Kawagoe-shi
2024-09-24
Active, closed
argenx
Phase 3
141
Chūōku, Fukuoka, Hanamaki-shi, Hiroshima, Kawagoe, Kyoto, Narita, Sapporo
2024-09-18
Recruiting
GlaxoSmithKline
Phase 3
440
Aichi, Fukuoka, Hiroshima, Hokkaido, Kanagawa, Miyagi, Miyazaki, Saitama
2024-09-11
Active, closed
Amgen
Phase 3
315
Nagoya, Funabashi-shi, Fukuoka, Iizuka-shi, Maebashi, Fukuyama, Hiroshima, Asahikawa
2024-09-09
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Hiroshima, Kashiwa-shi, Kure-shi, Minatoku, Nagasaki, Nagoya, Sakura-shi, Sapporo
2024-08-28
Active, closed
Ferring Pharmaceuticals
Observational
1,526
Chiba, Fukuoka, Kitakyushu, Takasaki, Hiroshima, Bunkyō City, Tokyo, Hokkaido
2024-08-27
Recruiting
AstraZeneca
Phase 3
620
Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi
2024-08-12
Active, closed
GlaxoSmithKline
Phase 3
10,212
Hiroshima, Ibaraki, Kumamoto, Okinawa, Saitama, Shizuoka, Tokyo, Yamagata
2024-08-01
Active, closed
Incyte Biosciences Japan GK
Phase 3
21
Aichi, Fukui, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2024-07-30
Active, closed
AstraZeneca
Observational
40
Chiba, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Mie, Okayama, Osaka
2024-07-16
Recruiting
AstraZeneca
Phase 3
240
Asahikawa-Shi, Bunkyō City, Chiba, Fukuoka, Hiroshima, Iruma-Gun, Kawachinagano-shi, Kawasaki-shi
2024-06-20
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Recruiting
AstraZeneca
Phase 3
675
Bunkyō City, Fukuoka, Hakodate-shi, Hidaka-shi, Hirakata-shi, Hirosaki-shi, Hiroshima, Kanazawa
2024-04-11
Active, closed
AstraZeneca
Phase 3
2,554
Chūōku, Daito-shi, Fujisawa-shi, Fukuoka, Hiroshima, Ina-shi, Kamakura-shi, Kasugai-shi
2024-03-29
Active, closed
Sanofi
Phase 3
464
Yokohama, Habikino, Sakai, Mibu, Minato, Tachikawa, Hiroshima, Sapporo
2024-02-29
Active, closed
Novo Nordisk A/S
Phase 2
88
Fukuoka, Hiroshima, Kumamoto-shi, Kumamoto, Nagano, Nagasaki, Okayama
2024-02-20
Recruiting
Eisai Co., Ltd.
Observational
5,000
Hiroshima, Kyoto, Tokyo
2024-02-14
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Yahatanishi-ku, Kitakyusyu-shi, Ota-shi, Hiroshima, Akashi-shi
2024-01-10
Active, closed
Pfizer
Phase 2
333
Otashi, Sendai, Suita, Chuo-ku, Chiba, Hiroshima, Osaka
2024-01-09
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Hiroshima, Iizuka-shi, Osaka, Sapporo, Yaizu-shi
2024-01-03
Recruiting
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Active, closed
AstraZeneca
Phase 3
760
Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Mitaka-shi, Nagoya, Osaka, Sendai
2023-12-04
Active, closed
AstraZeneca
Phase 3
863
Amagasaki-shi, Hakodate-shi, Hiroshima, Kitaadachi-gun, Kitakyushu-shi, Matsuyama, Nagoya, Nishinomiya-shi
2023-11-09
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
189
Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai
2023-11-01
Active, closed
Sound Wave Innovation CO., LTD.
Phase 3
220
Nagoya, Ōbu, Narita, Fukuoka, Hiroshima, Sapporo, Toride, Kanazawa
2023-10-31
Active, closed
Summit Therapeutics
Phase 3
1,600
Aichi, Fukuoka, Hirosaki, Hiroshima, Hokkaido, Kashihara, Matsumoto, Miyagi
2023-10-26
Recruiting
NRG Oncology
Phase 3
3,960
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Active, closed
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
Recruiting
Hiroshima University Hospital
Phase 1/2
7
Hiroshima
2023-09-21
Active, closed
Hoffmann-La Roche
Phase 3
687
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Ishikawa, Kanagawa
2023-09-14
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Chiba, Fukuoka, Koriyama-shi, Naka-gun, Hiroshima, Sapporo, Himeji-Shi, Kobe
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Gunma, Hiroshima, Hokkaido, Kanagawa, Miyagi, Shizuoka, Tokushima, Tokyo
2023-09-13
Recruiting
Hoffmann-La Roche
Phase 3
230
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama
2023-09-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Nankoku, Sakai, Koto, Hiroshima, Nagasaki, Osaka, Yamagata
2023-08-08
Active, closed
Hoffmann-La Roche
Phase 3
459
Aichi, Aomori, Chiba, Chūō, Ehime, Fukuoka, Hiroshima, Hokkaido
2023-08-08
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Shibukawa-shi, Kamakura-Shi, Kumamoto, Sunto-gun, Chiba, Gifu, Hiroshima, Isehara-shi
2023-06-22
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
By invitation
Eli Lilly and Company
Phase 3
333
Toyoake, Fukuyama, Hiroshima, Asahikawa, Sagamihara, Kyoto, Ina, Okayama
2023-03-09
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Fukui, Fukuoka, Gifu, Hiroshima, Kagawa, Kagoshima, Kanagawa, Nagano
2023-01-02
Active, closed
AstraZeneca
Phase 3
1,350
Bunkyō City, Chūōku, Hamamatsu, Hidaka-shi, Hirosaki-shi, Hiroshima, Kumamoto, Nagoya
2022-12-29
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
Hiroshima, Kanagawa, Osaka, Tokyo
2022-12-28
Active, closed
Ferring Pharmaceuticals
Phase 3
25
Nagakute-shi, Nagoya, Narita-shi, Matsuyama, Fukuoka, Hiroshima, Hakodate-shi, Sapporo
2022-12-21
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto
2022-12-15
Active, closed
Viatris Innovation GmbH
Phase 3
470
Amagasaki-shi, Bunkyō City, Chiba, Chuo-shi, Chūōku, Fukuoka, Hiroshima, Hitachi-Naka
2022-12-13
Recruiting
AstraZeneca
Phase 3
3,527
Chiba, Fukuoka, Gifu, Ginowan-shi, Hanyu-shi, Hiroshima, Hitachi-shi, Isehara-shi
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Aichi, Akita, Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima
2022-12-05
Active, closed
AstraZeneca
Phase 3
1,174
Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa
2022-11-28
Recruiting
National Cancer Center Hospital East
Phase 3
608
Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu
2022-11-21
Active, closed
AstraZeneca
Phase 3
368
Akita, Fukuoka, Himeji, Hiroshima, Isehara-shi, Kawasaki-shi, Maebashi, Minatoku
2022-11-10
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
100
Ehime, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima, Kanagawa
2022-11-04
Active, closed
Eli Lilly and Company
Phase 3
377
Asahikawa, Fukuyama, Habikino, Hiroshima, Ina, Kumagaya, Kyoto, Okayama
2022-10-18
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Abiko, Chikushino-shi, Fukuoka, Fukuoka-ken, Hiroshima, Kagoshima, Kashihara, Kashiwa
2022-09-27
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Asahikawa-shi, Chiba, Chūōku, Hiroshima, Kagoshima, Kawagoe-shi, Kita-gun, Sapporo
2022-09-16
Active, closed
AstraZeneca
Phase 3
341
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa
2022-08-03
Active, closed
Genentech, Inc.
Phase 3
373
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2022-08-03
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
15
Aichi, Fukuoka, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2022-07-12
Recruiting
Priothera SAS
Phase 3
366
Anjo-shi, Nagoya, Kanazawa, Osaka, Saitama, Shimotsuke-shi, Fukuoka, Hiroshima
2022-06-16
By invitation
Biogen
Phase 3
864
Nagoya, Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo, Himeji-shi
2022-06-10
Active, closed
AstraZeneca
Phase 3
644
Chūōku, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun, Kōtoku
2022-05-16
Recruiting
Innovacell GmbH
Phase 3
290
Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto
2022-05-11
Active, closed
AstraZeneca
Phase 3
760
Chūōku, Fukuoka, Hiroshima, Kashihara-shi, Kashiwa, Kumamoto, Mitaka-shi, Morioka
2022-03-28
Active, closed
BeOne Medicines
Phase 3
799
Matsuyama, Hiroshima, Sapporo, Kagoshima, Yokohama, KyotoShi, Okayama, Hirakata
2022-03-10
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Hiroshima, Niigata, Omura-shi, Shizuoka
2022-03-08
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
AstraZeneca
Phase 3
363
Bunkyō City, Chiba, Hiroshima, Kita-gun, Kitakyushu-shi, Matsumoto-shi, Nagasaki, Okayama
2022-02-15
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata
2022-02-07
Active, closed
AstraZeneca
Phase 3
1,051
Himeji-shi, Hiroshima, Kashiwa, Kurume-shi, Natori-shi, Niigata, Osaka, Sendai
2022-02-07
By invitation
UCB Biopharma SRL
Phase 3
300
Fukuoka, Hachioji-shi, Hiroshima, Hōfu, Itami, Kodaira, Koshi-shi, Kyoto
2022-02-03
Active, closed
GlaxoSmithKline
Phase 2
360
Gifu, Hiroshima, Hokkaido, Ishikawa, Kagawa, Kumamoto, Miyagi, Niigata
2021-12-14
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bunkyō City, Hiroshima, Kashiwa, Nagoya, Osaka, Osaka Sayama Shi, Sendai, Shimotsuke
2021-12-10
Recruiting
UCB Biopharma SRL
Phase 3
350
Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Hōfu, Itami, Kodaira, Koshi-shi
2021-12-07
Active, closed
Gilead Sciences
Phase 3
603
Asahikawa, Chūō, Fukui, Hirakata, Hiroshima, Hyōgo, Inzai, Iwakuni
2021-11-17
Recruiting
Pfizer
Phase 3
245
Nagoya, Azumino, Kashihara, Lruma-gun, Saitama-shi, Hiroshima, Saga
2021-11-17
Active, closed
AstraZeneca
Phase 3
927
Chūōku, Hidaka-shi, Hiroshima, Kawasaki-shi, Kōtoku, Nagoya, Ota-shi, Shinjuku-ku
2021-10-25
Active, closed
AstraZeneca
Phase 3
732
Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun
2021-10-18
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Isehara-Shi, Kumamoto-Shi Chuo-Ku, Naha, Osaka-Shi Chuo-Ku, Shinden, Koto-Ku, Fukushima, Hiroshima
2021-08-27
Active, closed
Biogen
Phase 3
562
Nagoya, Toyoake-shi, Chiba, Narashino-shi, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo
2021-07-16
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Chiba, Hanamaki, Hiroshima, Itabashi Ku, Kawasaki Shi, Kita Gun, Kumamoto, Nagoya
2021-07-15
Recruiting
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
European Foundation for Study of Chronic Liver Failure
Observational
3,000
Fukuoka, Hiroshima, Kyoto, Nagasaki, Tokyo
2021-07-08
Active, closed
GlaxoSmithKline
Phase 3
40
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Kagoshima, Kanagawa
2021-06-28
Recruiting
NRG Oncology
Phase 3
1,670
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
AstraZeneca
Phase 3
367
Chiba, Chūōku, Hamamatsu, Hiroshima, Itabashi-ku, Kita-gun, Kitakyushu-shi, Meguro-ku
2021-06-08
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
761
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Ibaraki, Kanagawa, Kyoto
2021-05-03
Active, closed
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Active, closed
Hoffmann-La Roche
Phase 3
557
Aichi, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Osaka, Tochigi
2021-04-26
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Nagoya, Sapporo, Kobe, Sendai, Osaka Sayama-shi, Kawagoe, Koto, Hiroshima
2021-04-08
Active, closed
Hoffmann-La Roche
Phase 3
342
Aichi, Chiba, Fukuoka, Hiroshima, Kanagawa, Osaka, Tokyo
2021-03-12
Recruiting
UCB Biopharma SRL
Phase 3
70
Bunkyō City, Chūō, Gifu, Hiroshima, Kodaira-shi, Kōshi, Kyoto, Nagoya
2021-03-11
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Active, closed
Daiichi Sankyo
Phase 3
1,600
Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku
2020-12-04
Active, closed
AstraZeneca
Phase 3
957
Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kochi, Kurume-shi
2020-11-17
Active, closed
AstraZeneca
Phase 3
640
Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku
2020-10-19
Active, closed
Hoffmann-La Roche
Phase 3
992
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2020-10-09
Active, closed
AstraZeneca
Phase 3
370
Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama
2020-10-02
Active, closed
argenx
Phase 2
229
Bunkyō City, Chiba, Fuchū, Fukuoka, Ginowan, Hakodate, Hiroshima, Kawagoe
2020-09-18
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
70
Chiba, Kashiwa, Matsuyama, Fukuoka, Kurume, Hiroshima, Sapporo, Akashi
2020-09-10
Active, closed
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
GlaxoSmithKline
Phase 3
242
Chiba, Ehime, Fukui, Gunma, Hiroshima, Hokkaido, Kagawa, Kanagawa
2020-07-14
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Aichi, Hiroshima, Hyōgo, Niigata, Osaka, Saitama, Shizuoka, Tokyo
2019-11-13
Active, closed
Bristol-Myers Squibb
Phase 3
461
Nagoya, Kashiwa-shi, Kitakyushu-shi, Hiroshima, Kobe, Kanazawa, Yokohama, Sendai
2019-11-05
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Nagoya, Kashiwa, Hiroshima, Matsuyama, Fukuoka, Sapporo, Nishinomiya, Tsukuba
2019-10-02
Active, closed
Multicentre Registry of CCTA, IVUS and OCT
NCT04066062Coronary Artery Disease
Cleerly, Inc.
Observational
1,700
Ehime, Hiroshima, Matsuyama, Okayama, Tokyo
2019-10-01
Recruiting
National Cancer Center Hospital East
Phase 3
110
Chiba, Gifu, Hidaka, Hirakata, Hiroshima, Izumo, Kanazawa, Kashiwa
2019-10-01
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 2/3
27
Fukui, Fukuoka, Gifu, Hiroshima, Hokkaido, Kanagawa, Kumamoto, Okayama
2019-09-01
Active, closed
BeOne Medicines
Phase 3
510
Nagoya, Toyohashi, Chiba, Kurume, Hiroshima, Yokohama, Kumamoto, Kyoto
2019-08-20
Active, closed
Sanofi
Observational
1,860
Sagamihara, Yokohama, Tsu, Habikino, Fuchū, Fukuoka, Fukuyama-shi, Hiroshima
2019-08-15
Active, closed
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
DrugsCis-platinum·CDDP·Tecentriq·Paraplatin
National Cancer Institute (NCI)
Phase 3
544
Sendai, Tōon, Sapporo, Kagoshima, Gunma, Niigata, Mitaka-shi, Hiroshima
2019-07-26
Active, closed
AstraZeneca
Phase 3
923
Bunkyō City, Fukuoka, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku, Kumamoto
2019-06-25
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Sapporo, Chuo-ku, Hiroshima, Kyoto
2019-06-13
Active, closed
AstraZeneca
Phase 3
724
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Kobe, Niigata
2019-03-06
Active, closed
AstraZeneca
Phase 2
367
Fukuoka, Hiroshima, Kanazawa, Nagoya, Niigata, Sapporo, Sayama, Sunto-gun
2019-01-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Nagoya, Kashiwa, Akashi, Kita-gun, Minato, Chiba, Fukuoka, Hiroshima
2018-12-17
Active, closed
AstraZeneca
Phase 3
825
Habikino-shi, Himeji-shi, Hiroshima, Iwakuni-shi, Kitaadachi-gun, Kitakyushu-shi, Kurashiki Shi, Nagoya
2018-12-06
Active, closed
AstraZeneca
Phase 3
724
Bunkyō City, Chiba, Chūōku, Fukuoka, Hiroshima, Kurume-shi, Musashino-shi, Nagoya
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,063
Bunkyō City, Fukuoka, Hirosaki-shi, Hiroshima, Kanazawa, Kōtoku, Kumamoto, Miyazaki
2018-11-16
Active, closed
AbbVie
Phase 3
265
Nagoya, Kashiwa-shi, Fukuoka, Ogaki-shi, Maebashi, Hiroshima, Kobe, Higashi Ibaraki-gun
2018-10-22
Active, closed
AbbVie
Phase 2
270
Nagoya, Hirosaki-shi, Chiba, Matsuyama, Fukuoka, Kurume-shi, Fukuyama, Hiroshima
2018-10-10
Active, closed
Hoffmann-La Roche
Phase 3
257
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2018-08-16
Active, closed
AbbVie
Phase 3
1,533
Nagoya, Fukuoka, Hiroshima, Sapporo, Amagasaki-shi, Sagamihara-shi, Yokohama, Kyoto
2018-08-09
Active, closed
AstraZeneca
Phase 3
216
Hiroshima, Kanazawa, Kashiwa, Nagoya, Niigata, Osaka, Sakaishi, Sapporo
2018-07-19
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Fukuoka, Hiroshima, Kanagawa, Sagamihara, Saitama, Tokyo, Toyoake
2018-05-14
Active, closed
AstraZeneca
Phase 3
1,324
Bunkyoku, Chiba, Fukuoka, Hiroshima, Iizuka, Kanazawa, Kōtoku, Kumamoto
2017-10-11
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Bunkyō City, Fukuoka, Hiroshima, Ishikawa, Kanagawa, Kyoto, Matsuyama, Miyagi
2017-09-22
Active, closed
NRG Oncology
Phase 3
162
Sapporo, Shiwa-gun, Mitaka-shi, Shinjuku-ku, Hiroshima, Saitama, Tokyo
2017-09-12
Active, closed
Eli Lilly and Company
Phase 3
5,637
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Ōta, Hiroshima, Sapporo
2017-07-12
Active, closed
AstraZeneca
Phase 3
1,186
Bunkyō City, Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2017-06-01
Active, closed
Bolton Medical
Not applicable
110
Nagoya, Hiroshima, Sapporo, Kashihara, Niigata, Yufu, Joto-ku, Suita
2017-05-10
Active, closed
Celgene
Phase 1/2
466
Matsuyama, Aomori, Hiroshima, Isehara City, Kanagawa, Kamogawa, Kyoto, Nagasaki, Nagoya
2016-10-14
Active, closed
Eisai Inc.
Phase 3
1,069
Aichi, Akita, Aomori, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo
2016-10-13
Active, closed
AstraZeneca
Phase 3
1,126
Akita, Bunkyō City, Fukuoka, Hakata-shi, Hirosaki-shi, Hiroshima, Izumo-shi, Kagoshima
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Bunkyō City, Fukuoka, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kitakyushu-shi, Kobe
2015-10-21
Active, closed
Eli Lilly and Company
Phase 3
453
Amagasaki, Asahikawa, Bunkyō City, Fukuoka, Habikino, Hirakata, Hiroshima, Hyōgo
2014-10-03
Active, closed
AstraZeneca
Phase 3
1,837
Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa
2014-04-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Akita, Fukuoka, Gifu, Hakodate, Hiroshima, Hokkaido, Kanazawa, Kashiwa
2013-10-14
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Bunkyō City, Hiroshima
2013-09-09
Recruiting
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Children's Hospital of Philadelphia
Observational
150,000
Setagaya-Ku, Hiroshima, Kobe, Ōbu, Saitama, Shimotsuke, Tokyo
2010-03
Active, closed
Genentech, Inc.
Phase 2
378
Hiroshima, Hyōgo
2008-10-16
Recruiting
Medtronic
Observational
20,000
Ageo, Bunkyō City, Gifu, Hidaka, Hiroshima, Kagoshima, Kamakura, Kawasaki
1983-01
Rows per page Showing 1–219 of 219
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/hiroshima

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 219 of those studies with a site in Hiroshima.

How many clinical trials are recruiting in Hiroshima?

86 of the 219 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 122 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hiroshima), 219 studies
PhaseStudiesRecruitingShare
Phase 31565971.2%
Phase 2291013.2%
Observational1155%
Not applicable733.2%
Phase 2/3632.7%
Phase 1/2522.3%
Phase 1331.4%
Phase 4210.9%

Most active sponsors

Lead sponsors with the most studies (Hiroshima)
Lead sponsorStudiesRecruiting
AstraZeneca5616
Hoffmann-La Roche133
GlaxoSmithKline114
Ono Pharmaceutical Co., Ltd.86
Eli Lilly and Company71
BeOne Medicines64
AbbVie51
argenx52
Bristol-Myers Squibb41
Sanofi42
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.